Financial Analysis: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)Defense World · Oct 18, 2026
CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial AnalysisDefense World · Oct 7, 2026
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 OutlookMarketBeat · Oct 2, 2026
Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head ContrastDefense World · Sep 28, 2026
Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume – What’s Next?Defense World · Sep 24, 2026
Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells $226,737.42 in StockDefense World · Sep 20, 2026Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | $0.07 | -$0.11 | Miss |
| May 7, 2026 | $0.03 | -$0.10 | Miss |
| Mar 19, 2026 | $0.44 | $0.06 | Miss |
| Nov 10, 2025 | -$0.12 | $0.04 | Beat |
| Aug 12, 2025 | -$0.09 | $1.08 | Beat |
| May 8, 2025 | -$0.21 | -$0.27 | Miss |